ArticleESMO open2026

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study.

F Moik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.